![Vaccines | Free Full-Text | Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar Vaccines | Free Full-Text | Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar](https://www.mdpi.com/vaccines/vaccines-11-01522/article_deploy/html/images/vaccines-11-01522-g001.png)
Vaccines | Free Full-Text | Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar
These early BioNTech investors just saw their faith rewarded with a $719 million payday - MarketWatch
![Can BioNTech's breakout year continue in 2022? Yes, due to COVID vaccine and pipeline | Seeking Alpha Can BioNTech's breakout year continue in 2022? Yes, due to COVID vaccine and pipeline | Seeking Alpha](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/medium_image_1307139993.jpg)
Can BioNTech's breakout year continue in 2022? Yes, due to COVID vaccine and pipeline | Seeking Alpha
![Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 | MMWR Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7102e1_PfizerMIS-C_IMAGE_07Jan22_SOCIAL_1200x675.jpg?_=63592)